Psychedelics represent a potential breakthrough for treatment-resistant depression; however, the prolonged in-clinic monitoring required for compounds such as psilocybin and lysergic acid diethylamide is a logistical hurdle to widespread use. Intranasal mebufotenin (5-methoxy-N,N-dimethyltryptamine), a 5-hydroxytryptamine 1A (5-HT1A) and 5-HT2A agonist associated with brief psychedelic...
This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.
Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed. To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study enrolled 198 adults aged 18 to 74 years with a...
This Viewpoint analyzes the Psychopharmacologic Drugs Advisory Committee’s decisions regarding 3,4-methylenedioxymethamphetamine–assisted therapy and what they mean for psychedelic research.
Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...
An increasing number of clinicians and researchers have become interested in the potential of psychedelic drugs for the treatment of mental health disorders, including depression, anxiety, posttraumatic stress disorder, eating disorders, and addictions.1,2
JAMADecember 13, 2022Eric J Lenze, Michelle Voegtle, J Philip Miller et al.
Episodic memory and executive function are essential aspects of cognitive functioning that decline with aging. This decline may be ameliorable with lifestyle interventions. To determine whether mindfulness-based stress reduction (MBSR), exercise, or a combination of both improve cognitive function in older adults. This 2 × 2 factorial randomized clinical trial was conducted at 2 US sites...
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck...
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck...
This Viewpoint reviews legalization initiatives for psychedelic substances and the concerns they raise by looking to the cautionary precedents involving the legalization and commercialization of other controlled substances.
This Viewpoint discusses recent evidence documenting benefits of nonpharmacological and drug therapies for major depressive disorder including exercise, Mediterranean diet and structured dietary support, ketamine and esketamine, anti-inflammatory drugs, brexanolone, and psilocybin.
This Viewpoint summarizes a number of important issues related to the clinical use of ketamine for the treatment of psychiatric disorders addressed in the consensus statement and provides suggestions for addressing remaining concerns.
CONTEXT: Primary care physicians report high levels of distress, which is linked to burnout, attrition, and poorer quality of care. Programs to reduce burnout before it results in impairment are rare; data on these programs are scarce. OBJECTIVE: To determine whether an intensive educational program in mindfulness, communication, and self-awareness is associated with improvement in primary care...
Chronic nightmares occur frequently in patients with posttraumatic stress disorder (PTSD) but are not usually a primary target of treatment. To determine if treating chronic nightmares with imagery rehearsal therapy (IRT) reduces the frequency of disturbing dreams, improves sleep quality, and decreases PTSD symptom severity. Randomized controlled trial conducted from 1995 to 1999 among 168...
To the Editor. —We have recently presented data 1 from our annual survey of 522 328 junior and senior school students from schools across the United States. This anonymous questionnaire on the prevalence of drug use was administered to all junior and senior students attending home rooms in these schools in 1993, and results were compared with 1992. Hallucinogen use increased significantly ( P t...
To the Editor. — I read with great interest the article by Dr Wagner 1 proposing that peace through mind/brain science may be an idea whose time has come. An obvious stumbling block is that the perpetrators of violence and belligerent behavior may not be available to be treated medically and/or that the numbers of those treated may not be sufficient to change societal trends. Recent data point...
To the Editor.— Descriptions of the experience of surviving near-death events are entertaining,1but should be interpreted with caution. Report of a Case.— A 40-year-old woman with normal findings on physical examination except for breakaway weakness and nonanatomic sensory loss, underwent myelography for long-term lower back pain. Immediately after subarachnoid instillation of iohexol she...
(+/-)3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug that has been proposed to be useful as an adjunct to psychotherapy. This study assessed the neurotoxic potential of MDMA in nonhuman primates. Monkeys were repeatedly administered doses (2.50, 3.75, and 5.00 mg/kg) of MDMA subcutaneously and analyzed for regional brain content of serotonin and 5-hydroxyindoleacetic...
To the Editor. —Drs Brown and Osterloh,1in a recent letter inTHE JOURNAL, reported a nearly fatal toxic reaction to 3,4-methylenedioxymethamphetamine (MDMA). The estimated dose of MDMA administered was 100 to 150 mg and the blood levels, measured at one and two hours after hospital admission, were 6500 and 7000 ng/mL, respectively. Before MDMA became a Schedule 1 drug on July 1, 1985,2it was...
To the Editor.— We would like to report the case of a young woman who suffered serious but reversible toxic reactions from a recreational dose of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and whose blood levels of MDMA were much higher than in any of the fatalities reported by Dowling et al.1 Report of a Case.— A 32-year-old woman and her friend, both of whom had used MDMA before,...
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"), a synthetic analogue of 3,4-methylenedioxyamphetamine, has been the center of recent debate over its potential for abuse vs its use as a psychotherapeutic agent. Following its emergency classification in Schedule 1 by the Drug Enforcement Administration in 1985, 3,4-methylenedioxyethamphetamine (MDEA, "Eve") has appeared as MDMA's legal...
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"), a synthetic analogue of 3,4-methylenedioxyamphetamine, has been the center of recent debate over its potential for abuse vs its use as a psychotherapeutic agent. Following its emergency classification in Schedule 1 by the Drug Enforcement Administration in 1985, 3,4-methylenedioxyethamphetamine (MDEA,"Eve") has appeared as MDMA's legal...